Developmental programming of pediatric nonalcoholic fatty liver disease: Redefining the first hit

Clinical Obstetrics and Gynecology

Volumn 56, Issue 3, 2013, Pages 577-590

  Stewart, Michael S ^a   Heerwagen, Margaret J R ^a   Friedman, Jacob E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

fetal programming; lipotoxicity; maternal obesity; mitochondrial dysfunction; NAFLD; nonalcoholic steatohepatitis; pediatric NASH; sirtuins

Indexed keywords

LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN;

CHILDHOOD DISEASE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FATTY LIVER; FETUS LIVER; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIPID STORAGE; LIPOTOXICITY; LIVER DEVELOPMENT; MATERNAL OBESITY; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; MORPHOGENESIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

CHILD; FATTY LIVER; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIVER; MITOCHONDRIA; OBESITY; OXIDATIVE STRESS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84882453072     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3182a09760     Document Type: Review

References (109)

1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-530.
2. Moran JR, Ghishan FK, Halter SA, et al. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol. 1983;78: 374-377.
3. Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133:1814-1820.
4. Wiegand S, Keller KM, Robl M, et al. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents. Int J Obes (Lond). 2010;34:1468-1474.
5. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162:496-500.
6. Barshop NJ, Francis CS, Schwimmer JB, et al. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. PedHealth. 2009;3:271-281.
7. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307:483-490.
8. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393.
9. Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol. 2006;4:226-232.
10. Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371-379.
11. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of nonalcoholic fatty liver disease in children: a followup study for up to 20 years. Gut. 2009;58: 1538-1544.
12. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
13. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641-649.
14. Nobili V, Marcellini M, Devito R, et al.NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458-465.
15. Day CP, James OF. Steatohepatitis: a tale of two "hits" Gastroenterology. 1998;114:842-845.
16. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52: 1836-1846.
17. Thaler H. Relation of steatosis to cirrhosis. Clin Gastroenterol. 1975;4:273-280.
18. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-1374.
19. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519-1523.
20. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12: 1106-1110.
21. Mager DR, Patterson C, So S, et al. Dietary and physical activity patterns in children with fatty liver. Eur J Clin Nutr. 2010;64:628-635.
22. Fishbein MH, Mogren C, Gleason T, et al. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2006; 42:83-88.
23. Burgert TS, Taksali SE, Dziura J, et al. Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab. 2006;91:4287-4294.
24. Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-505.
25. Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut. 2008;57:1283-1287.
26. Manco M, Marcellini M, Devito R, et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32:381-387.
27. Day CP. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Dig Dis. 2010;28:255-260.
28. Godlewski G, Gaubert-Cristol R, Rouy S, et al. Liver development in the rat and in man during the embryonic period (Carnegie stages 11-23). Microsc Res Tech. 1997;39:314-327.
29. Zaret KS. Liver specification and early morphogenesis. Mech Dev. 2000;92:83-88.
30. Gualdi R, Bossard P, Zheng M, et al. Hepatic specification of the gut endoderm in vitro: cell signaling and transcriptional control. Genes Dev. 1996;10:1670-1682.
31. Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology. 2009;137:62-79.
32. Xanthopoulos KG, Mirkovitch J. Gene regulation in rodent hepatocytes during development, differentiation and disease. Eur J Biochem. 1993;216:353-360.
33. Dame C, Juul SE. The switch from fetal to adult erythropoiesis. Clin Perinatol. 2000;27:507-526.
34. Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007;261:412-417.
35. Lucas A. Programming by early nutrition in man. Ciba Found Symp. 1991;156:38-55.
36. Fowden AL, Giussani DA, Forhead AJ. Intrauterine programming of physiological systems: causes and consequences. Physiology (Bethesda). 2006;21:29-37.
37. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595-601.
38. Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 1993;36:62-67.
39. Aviram A, Hod M, Yogev Y. Maternal obesity: implications for pregnancy outcome and longterm risks-a link to maternal nutrition. Int J Gynaecol Obstet. 2011;115 (suppl 1):S6-S10.
40. Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005;115:e290-e296.
41. Catalano PM, Farrell K, Thomas A, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009; 90:1303-1313.
42. Oben JA, Mouralidarane A, Samuelsson AM, et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. J Hepatol. 2010;52:913-920.
43. George LA, Uthlaut AB, LongNM,et al. Different levels of overnutrition and weight gain during pregnancy have differential effects on fetal growth and organ development. Reprod Biol Endocrinol. 2010;8:75.
44. Srinivasan M, Katewa SD, Palaniyappan A, et al. Maternal high-fat diet consumption results in fetal malprogramming predisposing to the onset of metabolic syndrome-like phenotype in adulthood. Am J Physiol Endocrinol Metab. 2006;291:E792-E799.
45. McCurdy CE, Bishop JM, Williams SM, et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest. 2009;119:323-335.
46. Brumbaugh DE, Tearse P, Cree-Green M, et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr. 2013;162:930-936.
47. Modi N, Murgasova D, Ruager-Martin R, et al. The influence of maternal body mass index on infant adiposity and hepatic lipid content. Pediatr Res. 2011;70:287-291.
48. Bernstein IM, Goran MI, Amini SB, et al. Differential growth of fetal tissues during the second half of pregnancy. Am J Obstet Gynecol. 1997; 176:28-32.
49. Widdowson EM. Growth and composition of the fetus and newborn. In: Assali NS, ed. The Biology of Gestation. New York: Academic Press; 1968: 1-49.
50. Salameh WA, Mastrogiannis DS. Maternal hyperlipidemia in pregnancy. Clin Obstet Gynecol. 1994;37:66-77.
51. Catalano PM, Ehrenberg HM. The short-and long-term implications of maternal obesity on the mother and her offspring. BJOG. 2006;113: 1126-1133.
52. Dube E, Gravel A, Martin C, et al. Modulation of fatty acid transport and metabolism by maternal obesity in the human full-term placenta. Biol Reprod. 2012;87:1-11.
53. Zhu MJ, Ma Y, Long NM, et al. Maternal obesity markedly increases placental fatty acid transporter expression and fetal blood triglycerides at midgestation in the ewe. Am J Physiol Regul Integr Comp Physiol. 2010;299: R1224-R1231.
54. Cheung O, Sanyal AJ. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:351-359.
55. Haggarty P. Fatty acid supply to the human fetus. Annu Rev Nutr. 2010;30:237-255.
56. Battaglia FC, Meschia G. Principal substrates of fetal metabolism. Physiol Rev. 1978;58: 499-527.
57. Browning MF, Levy HL, Wilkins-Haug LE, et al. Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. Obstet Gynecol. 2006;107:115-120.
58. Bruce KD, Cagampang FR, Argenton M, et al. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology. 2009;50:1796-1808.
59. Borengasser SJ, Lau F, Kang P, et al. Maternal obesity during gestation impairs fatty acid oxidation and mitochondrial SIRT3 expression in rat offspring at weaning. PLoS One. 2011;6: e24068.
60. Kohjima M, Enjoji M, Higuchi N, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007;20:351-358.
61. Wei Y, Rector RS, Thyfault JP, et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008;14: 193-199.
62. Demeilliers C, Maisonneuve C, Grodet A, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology. 2002;123:1278-1290.
63. Bayol SA, Simbi BH, Fowkes RC, et al. A maternal "junk food" diet in pregnancy and lactation promotes nonalcoholic fatty liver disease in rat offspring. Endocrinology. 2010;151: 1451-1461.
64. Sato EF, Nakagawa E, Hiramoto K, et al. Oxidative stress promotes the regression of fetal liver hemopoiesis. Biochemistry (Mosc). 2004; 69:18-22.
65. Sen S, Simmons RA. Maternal antioxidant supplementation prevents adiposity in the offspring of western diet-fed rats. Diabetes. 2010;59: 3058-3065.
66. Luzzo KM, Wang Q, Purcell SH, et al. High fat diet induced developmental defects in the mouse: oocyte meiotic aneuploidy and fetal growth retardation/brain defects. PLoS One. 2012;7:e49217.
67. Newsom SA, Boyle KE, Friedman JE. Sirtuin 3: a major control point for obesity-related metabolic diseases Drug Discov Today. 2013; DOI: 10.1016/j.ddmec.2013.04.001.
68. Qiu X, Brown K, Hirschey MD, et al. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12: 662-667.
69. Bao J, Scott I, Lu Z, et al. SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic Biol Med. 2010; 49:1230-1237.
70. Kendrick AA, Choudhury M, Rahman SM, et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011;433:505-514.
71. Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9:327-338.
72. Suter MA, Chen A, Burdine MS, et al. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. Faseb J. 2012;26:5106-5114.
73. Yeon JE, Choi KM, Baik SH, et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2004;19:799-804.
74. Kong X, Wang R, Xue Y, et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One. 2010;5:e11707.
75. Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1 alpha promoter. Hepatology. 2010;52:1992-2000.
76. Gemma C, Sookoian S, Alvarinas J, et al. Maternal pregestational BMI is associated with methylation of the PPARGC1A promoter in newborns. Obesity (Silver Spring). 2009;17: 1032-1039.
77. Burgueno AL, Cabrerizo R, Gonzales Mansilla N, et al. Maternal high-fat intake during pregnancy programs metabolic-syndrome-related phenotypes through liver mitochondrial DNA copy number and transcriptional activity of liver PPARGC1A. J Nutr Biochem. 2013;24:6-13.
78. Gao Z, Zhang J, Kheterpal I, et al. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem. 2011;286:22227-22234.
79. Fritz KS, Galligan JJ, Smathers RL, et al. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol. 2011;24: 651-662.
80. Schmatz M, Madan J, Marino T, et al. Maternal obesity: the interplay between inflammation, mother and fetus. J Perinatol. 2010;30:441-446.
81. Grant WF, Gillingham MB, Batra AK, et al. Maternal high fat diet is associated with decreased plasma n-3 fatty acids and fetal hepatic apoptosis in nonhuman primates. PLoS One. 2011;6:e17261.
82. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factoralpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
83. Catalano PM, Presley L, Minium J, et al. Fetuses of obese mothers develop insulin resistance in utero. Diabetes Care. 2009;32:1076-1080.
84. Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the pedersen hypothesis in the face of the obesity epidemic Am J Obstet Gynecol. 2011;204:479-487.
85. Ashino NG, Saito KN, Souza FD, et al. Maternal high-fat feeding through pregnancy and lactation predisposes mouse offspring to molecular insulin resistance and fatty liver. J Nutr Biochem. 2012;23:341-348.
86. Mouralidarane A, Soeda J, Visconti-Pugmire C, et al. Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice. Hepatology. 2013; DOI: 10.1002/hep.26248.
87. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51: 212-223.
88. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116: 3015-3025.
89. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-194.
90. Romics L Jr, Dolganiuc A, Kodys K, et al. Selective priming to toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in mice. Hepatology. 2004;40:555-564.
91. De Nardo D, De Nardo CM, Nguyen T, et al. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages. J Immunol. 2009;183:8110-8118.
92. Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010;2010: DOI: 10.1155/2010/192543.
93. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 2007;56: 1986-1998.
94. Li J, Huang J, Li JS, et al. Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J Hepatol. 2012;56:900-907.
95. Matsumoto M, Han S, Kitamura T, et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest. 2006;116:2464-2472.
96. Perfield JW II, Ortinau LC, Pickering RT, et al. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient ob/ob mice. J Obes. 2013; doi: 10.1155/2013/296537.
97. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177.
98. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118: 511-521.
99. Kalliomaki M, Collado MC, Salminen S, et al. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87:534-538.
100. Trasande L, Blustein J, Liu M, et al. Infant antibiotic exposures and early-life body mass. Int J Obes (Lond). 2013;37:16-23.
101. Ajslev TA, Andersen CS, Gamborg M, et al. Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond). 2011;35: 522-529.
102. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
103. Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring). 2011;19:476-482.
104. Harte AL, da Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010;7: 15; DOI: 10.1186/1476-9255-7-15.
105. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645-649.
106. Aron-Wisnewsky J,GaboritB,DutourA, et al.Gut microbiota and non-alcoholic fatty liver disease: new insights. ClinMicrobiol Infect. 2013;19:338-348.
107. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18: 190-195.
108. Zambell KL, Fitch MD, Fleming SE. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J Nutr. 2003;133:3509-3515.
109. Frasinariu OE, Ceccarelli S, Alisi A, et al. Gutliver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45:543-551.